Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92290 Châtenay-Malabry, France; Laboratoire de Pharmacie Galénique, Cosmétologie et Législation Pharmaceutique, UFR des Sciences Pharmaceutiques et Biologiques d'Abidjan, Université Félix Houphouet-Boigny, 01 BP V 34 Abidjan 01, Côte d'Ivoire.
INRAE, AgroParisTech, MIcalis Institute, Équipe Bactéries pathogènes et santé, Université Paris-Saclay, 92290 Châtenay-Malabry, France.
Int J Pharm. 2020 Oct 15;588:119733. doi: 10.1016/j.ijpharm.2020.119733. Epub 2020 Aug 5.
The increasing resistance of Neisseria gonorrhoeae to any current antibiotic treatment and the difficulties associated with the use of prevention means such as condom urge the need for alternative methods to prevent this sexually transmitted infection. In this work, a prevention strategy based on the use of a vaginal gel containing Lactobacilli was assessed in vitro. A Lactobacillus crispatus strain (ATCC 33197) was selected based on the published data on its ability to inhibit Neisseria gonorrhoeae. Its probiotic properties were first characterized. Then, a thermo-sensitive hydrogel containing 21.5% of poloxamer 407, 1% of sodium alginate and 9log CFU of Lactobacillus crispatus per gel sample (5 g) was developed. The gelation temperature and the rheological characteristics of this formulation appeared suitable for a vaginal administration. Lactobacillus crispatus was viable in the gel for six months although a large amount of the bacteria was not culturable. The ability of Lactobacillus crispatus to inhibit Neisseria gonorrhoeae was still observed with the gel. Such system, thus, appeared promising for the prevention of gonorrhea.
淋病奈瑟菌对任何当前抗生素治疗的耐药性不断增加，以及预防手段（如避孕套）的使用所带来的困难，都促使人们需要寻找替代方法来预防这种性传播感染。在这项工作中，评估了基于使用含有乳酸菌的阴道凝胶的预防策略。根据已发表的关于其抑制淋病奈瑟菌的能力的数据，选择了一株乳酸杆菌卷曲（ATCC 33197）。首先对其益生菌特性进行了表征。然后，开发了一种含有 21.5%泊洛沙姆 407、1%海藻酸钠和每凝胶样品（5 克）9log CFU 乳酸杆菌卷曲的温敏水凝胶。该配方的胶凝温度和流变特性似乎适合阴道给药。尽管大量细菌不可培养，但乳酸杆菌卷曲在凝胶中仍具有活力。凝胶仍能观察到乳酸杆菌卷曲抑制淋病奈瑟菌的能力。因此，这种系统有望预防淋病。
